A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT) IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS.

Trial Profile

A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT) IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Panobinostat (Primary) ; Thalidomide (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top